Timber Pharmaceuticals, Inc., (NYSE American: TMBR) (Timber or “the company"), formerly known as BioPharmX Corporation, a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, announced the closing of its merger with Lowenstein client Timber Pharmaceuticals LLC (Timber LLC). The combined company will be managed by the former Timber LLC executives and operate under the name “Timber Pharmaceuticals, Inc.” Its shares commenced trading on the NYSE American market at the open of trading on May 19, 2020, under the ticker symbol "TMBR.”
Immediately prior to the merger, Timber LLC completed a private placement financing resulting in gross proceeds of $25 million under the terms of the securities purchase agreement previously announced in March 2020. The merger expands resources and expertise to build momentum in development programs targeting new therapies for underserved patient populations living with some of the most serious conditions in medical dermatology.
The merger was originally announced on January 28, 2020.
The Lowenstein deal team included Steven M. Skolnick, Alan Wovsaniker, Alexander Dinur, Sarah P. Cole, and Tracy F. Buffer.
About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with over 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.
